Progestogen only contraception in women with congenital heart disease
Background There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.Objective To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (P...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Obstetrics and Gynaecology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/01443615.2024.2320296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553127179812864 |
|---|---|
| author | Francesc Baró-Mariné Antonia Pijuan-Domènech Maria del Mar Goya Elena Suárez-Edo Berta Miranda-Barrio Laura Dos-Subirà Maria Luisa Pancorbo Ignacio Ferreira-Gonzalez Elena Carreras-Moratonas |
| author_facet | Francesc Baró-Mariné Antonia Pijuan-Domènech Maria del Mar Goya Elena Suárez-Edo Berta Miranda-Barrio Laura Dos-Subirà Maria Luisa Pancorbo Ignacio Ferreira-Gonzalez Elena Carreras-Moratonas |
| author_sort | Francesc Baró-Mariné |
| collection | DOAJ |
| description | Background There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.Objective To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs).Study design Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected.Results Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (p < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively.Conclusions Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD. |
| format | Article |
| id | doaj-art-0c63f8898bbe486788a1dfe6b60a5ed9 |
| institution | Kabale University |
| issn | 0144-3615 1364-6893 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Obstetrics and Gynaecology |
| spelling | doaj-art-0c63f8898bbe486788a1dfe6b60a5ed92025-01-09T12:13:17ZengTaylor & Francis GroupJournal of Obstetrics and Gynaecology0144-36151364-68932024-12-0144110.1080/01443615.2024.2320296Progestogen only contraception in women with congenital heart diseaseFrancesc Baró-Mariné0Antonia Pijuan-Domènech1Maria del Mar Goya2Elena Suárez-Edo3Berta Miranda-Barrio4Laura Dos-Subirà5Maria Luisa Pancorbo6Ignacio Ferreira-Gonzalez7Elena Carreras-Moratonas8Department of Obstetrics and Gynaecology, University Hospital Vall d’Hebron, Barcelona, SpainIntegrated Hospital Vall d’Hebron-Hospital Sant Pau Adult Congenital Heart Disease Unit, University Hospital Vall d’Hebron, Barcelona, SpainDepartment of Obstetrics and Gynaecology, University Hospital Vall d’Hebron, Barcelona, SpainDepartment of Anesthesiology, Hospital Vall d’Hebron, Barcelona, SpainIntegrated Hospital Vall d’Hebron-Hospital Sant Pau Adult Congenital Heart Disease Unit, University Hospital Vall d’Hebron, Barcelona, SpainIntegrated Hospital Vall d’Hebron-Hospital Sant Pau Adult Congenital Heart Disease Unit, University Hospital Vall d’Hebron, Barcelona, SpainDepartment of Obstetrics and Gynaecology, University Hospital Vall d’Hebron, Barcelona, SpainDepartment of Cardiology, University Hospital Vall d’Hebron, CIBER-CV, Barcelona, SpainDepartment of Obstetrics and Gynaecology, University Hospital Vall d’Hebron, Barcelona, SpainBackground There is little information of progestogen-only contraceptives in patients with congenital heart disease (CHD) on the long-term.Objective To evaluate the use of contraception in patients with CHD. We studied both short-acting reversible contraceptives (SARCs), oral progestin-only pills (POPs) and long-acting reversible contraceptives (LARCs): intrauterine devices (IUD-IPs) and subdermal implants both impregnated with progestogens (SI-IPs).Study design Retrospective study of all women attending the preconception clinic. Contraceptive methods were classified in three TIERs of effectiveness before and after consultation. ESC classification regarding pregnancy risk, WHOMEC classification for combined oral contraceptive safety was collected.Results Six hundred and fifty-three patients. A significant proportion of them switched from TIER 3 to TIER 2 or 1 (p < .001) after consultation. One hundred and ninety-nine patients used POPs, 53 underwent IUD-IPs implantation and 36 SI-IPs, mean duration was 58 ± 8, 59 ± 8 and 53 ± 38 months, respectively.Conclusions Because of their safety and efficacy, IUD-IPs and SI-IPs should be considered as first-line contraception in patients with CHD.https://www.tandfonline.com/doi/10.1080/01443615.2024.2320296Congenital heart diseaseprogesterone only contraceptionLARCs methods (long-acting reversible contraceptive)SARCs methods (short-acting reversible contraceptive) |
| spellingShingle | Francesc Baró-Mariné Antonia Pijuan-Domènech Maria del Mar Goya Elena Suárez-Edo Berta Miranda-Barrio Laura Dos-Subirà Maria Luisa Pancorbo Ignacio Ferreira-Gonzalez Elena Carreras-Moratonas Progestogen only contraception in women with congenital heart disease Journal of Obstetrics and Gynaecology Congenital heart disease progesterone only contraception LARCs methods (long-acting reversible contraceptive) SARCs methods (short-acting reversible contraceptive) |
| title | Progestogen only contraception in women with congenital heart disease |
| title_full | Progestogen only contraception in women with congenital heart disease |
| title_fullStr | Progestogen only contraception in women with congenital heart disease |
| title_full_unstemmed | Progestogen only contraception in women with congenital heart disease |
| title_short | Progestogen only contraception in women with congenital heart disease |
| title_sort | progestogen only contraception in women with congenital heart disease |
| topic | Congenital heart disease progesterone only contraception LARCs methods (long-acting reversible contraceptive) SARCs methods (short-acting reversible contraceptive) |
| url | https://www.tandfonline.com/doi/10.1080/01443615.2024.2320296 |
| work_keys_str_mv | AT francescbaromarine progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT antoniapijuandomenech progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT mariadelmargoya progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT elenasuarezedo progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT bertamirandabarrio progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT lauradossubira progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT marialuisapancorbo progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT ignacioferreiragonzalez progestogenonlycontraceptioninwomenwithcongenitalheartdisease AT elenacarrerasmoratonas progestogenonlycontraceptioninwomenwithcongenitalheartdisease |